Contract · Federal

Notice of Intent to Sole Source Serology DV-1-4 EDIII Reagents

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF / CENTERS FOR DISEASE CONTROL AND PREVENTION
Location: Atlanta, GA
Amount: Amount not listed
Posted: Jul 22, 2026
Set-aside: None (open competition)
NAICS code: 325413 look up NAICS codes
PSC code: 6640

Timeline

Posted

Jul 22, 2026
Status

Closing soon

What contracts like this typically pay

No award history yet for this category (NAICS 325413).

What this contract is for

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF / CENTERS FOR DISEASE CONTROL AND PREVENTION
Location: Atlanta, GA
NAICS: 325413
Scope: Federal

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order/contract to UNIVERSITY OF NORTH CAROLINA -CH Microbiology & Immunology for custom-produced biotinylated EDIII antigens for Zika virus and dengue virus serotypes 1–4 are specifically designed for the CDC flavivirus serologic assay development and validation using streptavidin-based capture and multiplex immunoassay platforms.

The requested HaloTag control antigen also provides a matched control for assessing nonspecific binding, assay background, and reagent-related signal.

Published assay validation work using EDIII antigens demonstrated high sensitivity and specificity for distinguishing prior dengue and Zika virus exposure, supporting the technical need for these specialized reagents.

Commercially available whole-virus antigens, full-length envelope proteins, NS1 antigens, non-biotinylated recombinant EDIII antigens, and generic flavivirus assay reagents were considered.

However, these alternatives do not meet the Branch’s technical requirements.

Whole-virus and full-length flavivirus antigens contain conserved epitopes that can produce substantial cross-reactive antibody binding between dengue and Zika viruses, reducing assay specificity.

Non-biotinylated or differently tagged antigens are not suitable substitutes because the current assay workflow depends on biotin–streptavidin capture for stable antigen immobilization, consistent antigen orientation, and reproducible assay conditions.

Generic or off-the-shelf antigens also may differ in sequence, tag configuration, purity, lot consistency, or manufacturing method, which could introduce unacceptable variability and compromise comparability with existing validation data and ongoing laboratory protocols.

Use of altern...

Official solicitation and documents

The full solicitation, any attachments, and the actual submission instructions live on the official listing, not on this page. Oppward summarizes public record data; it does not host or mirror the source documents.

View the official listing on SAM.gov

Oppward is an independent service and is not affiliated with, endorsed by, or sponsored by SAM.gov or any government agency. This page is a plain-English summary of public record data; the linked source above is the authoritative listing.

How to bid on this

This is a contract solicitation, not a grant. To bid, you submit a proposal (usually a price and a description of how you would do the work) directly to the government, through the channel the official listing specifies, not through Oppward.

Make sure your business has an active SAM.gov registration. You cannot be paid on a federal contract without one.
Read the full solicitation on the official listing above, especially the scope of work, not just this summary. Our guide to reading a solicitation walks through what to look for.
This listing has no set-aside restriction ("full and open competition"), meaning any business, large or small, can bid.
Submit your proposal by the deadline, using the exact submission method the official listing states. A technically on-time bid sent the wrong way is often treated as late.